Takeda Brings Rare Disease Drugs To India But Access Questions Linger
Executive Summary
Takeda has introduced rare disease therapies from Shire’s portfolio in India and appears to be shifting gears in a market where it has long adopted a measured approach. But pricing and access to these products pose challenges that the Japanese multinational will need to address.
You may also be interested in...
Takeda Exec On Access Strategies To Fit Local Contexts, Trial Inclusivity
Takeda’s president, growth and emerging markets, talks to Scrip about keeping decisions “as close to patients as possible” as the company seeks to widen access to its therapies and address gaps in health equity across the value chain including the trials arena.
Takeda Expands Hemophilia Play In India But Hemlibra Has Made Inroads
Takeda dips into the ex-Shire portfolio to debut Adynovate in India, where a large number of hemophilia patients remain undiagnosed. The extended half-life recombinant Factor VIII treatment, though, will need to take on competitors like Roche’s blockbuster, Hemlibra, which has seen rapid adoption in reimbursement ecosystems where it is included in the formulary
It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support
Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.